These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1108 related articles for article (PubMed ID: 17762545)

  • 41. [Hormone replacement in postmenopausal women with coronary heart disease. Results and clinical consequences from recent studies].
    Schurz RA; Benzer W
    Wien Klin Wochenschr; 1997; 109 Suppl 2():42-5. PubMed ID: 9340923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis.
    Phillips LS; Langer RD
    Fertil Steril; 2005 Mar; 83(3):558-66. PubMed ID: 15749481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Letter by Lehmann regarding articles "Electrocardiographic abnormalities that predict coronary heart disease events and mortality in postmenopausal women: the Women's Health Initiative" and "Electrocardiographic predictors of incident congestive heart failure and all-cause mortality in postmenopausal women: the Women's Health Initiative".
    Lehmann MH
    Circulation; 2006 Jun; 113(23):e854. PubMed ID: 16769921
    [No Abstract]   [Full Text] [Related]  

  • 44. Controversial aspects of hormone replacement therapy upon cardiovascular mortality and morbidity of women in menopause.
    Rosano GM; Mercuro G
    G Ital Cardiol; 1999 Sep; 29(9):999-1003. PubMed ID: 10514956
    [No Abstract]   [Full Text] [Related]  

  • 45. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research.
    Henderson VW
    Neuroscience; 2006; 138(3):1031-9. PubMed ID: 16310963
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Coronary heart disease risk factors in women.
    Brochier ML; Arwidson P
    Eur Heart J; 1998 Feb; 19 Suppl A():A45-52. PubMed ID: 9519343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Electrocardiographic abnormalities that predict coronary heart disease events and mortality in postmenopausal women: the Women's Health Initiative.
    Rautaharju PM; Kooperberg C; Larson JC; LaCroix A
    Circulation; 2006 Jan; 113(4):473-80. PubMed ID: 16449726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of postmenopausal hormone therapy on cardiovascular risk.
    Rossouw JE
    J Hypertens Suppl; 2002 May; 20(2):S62-5. PubMed ID: 12183856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women estrogen replacement from the cardiologist's perspective.
    Mobasseri S; Liebson PR; Klein LW
    Cardiol Rev; 2004; 12(6):287-98. PubMed ID: 15476565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Postmenopausal hormone therapy before and after the women's health initiative study: what consequences?
    Mikkola TS; Clarkson TB; Notelovitz M
    Ann Med; 2004; 36(6):402-13. PubMed ID: 15513292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Hormone replacement therapy and cardiovascular pathology in menopause].
    Micheli S; Marcucci R; Farsi A; Abbate R
    Ann Ital Med Int; 1998; 13(1):37-46. PubMed ID: 9642841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones.
    Rossouw JE
    Maturitas; 2005 May; 51(1):51-63. PubMed ID: 15883110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hormone therapy and the cardiovascular system: the critical role of progestins.
    Sitruk-Ware RL
    Climacteric; 2003 Oct; 6 Suppl 3():21-8. PubMed ID: 15018245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of nutrition in the prevention of coronary heart disease in women of the developed world.
    Greene CM; Fernandez ML
    Asia Pac J Clin Nutr; 2007; 16(1):1-9. PubMed ID: 17215174
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study.
    Smoller JW; Pollack MH; Wassertheil-Smoller S; Jackson RD; Oberman A; Wong ND; Sheps D
    Arch Gen Psychiatry; 2007 Oct; 64(10):1153-60. PubMed ID: 17909127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials).
    Robinson JG; Wallace R; Limacher M; Ren H; Cochrane B; Wassertheil-Smoller S; Ockene JK; Blanchette PL; Ko MG
    Am J Cardiol; 2008 Sep; 102(6):693-9. PubMed ID: 18773990
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hormone replacement therapy post Women's Health Initiative study: where do we stand?
    Calleja-Agius J; Brincat MP
    Curr Opin Obstet Gynecol; 2008 Dec; 20(6):513-8. PubMed ID: 18989125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention.
    Vitale C; Miceli M; Rosano GM
    Climacteric; 2007 Oct; 10 Suppl 2():16-20. PubMed ID: 17882667
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coronary heart disease and hormone replacement therapy - from primary and secondary prevention to the window of opportunity.
    Fait T; Vrablik M
    Neuro Endocrinol Lett; 2012; 33 Suppl 2():17-21. PubMed ID: 23183504
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Prevention of cardiovascular diseases by hormone replacement in postmenopause].
    Windler E
    Zentralbl Gynakol; 1996; 118(4):188-97. PubMed ID: 8651005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.